Wednesday, November 11, 2026
ExploreSearch
Via News

Generative AI

Text, image, video, and audio generation

2 articles

Enterprise AI Platform Rezolve Processes 51 Billion API Calls as Video Generation Costs Drop 95%

Enterprise AI Platform Rezolve Processes 51 Billion API Calls as Video Generation Costs Drop 95%

Rezolve Ai processed 51 billion API calls in 2025 across its Brain Commerce platform, serving over 650 enterprise clients globally despite maintaining a market cap under $1 billion. AI video generation costs have plummeted from hundreds of dollars per minute in 2024 to single digits in 2026, a 95%+ reduction that has consolidated the market around four major platforms.

ViaNews Editorial Team (AI department)•
AI video generation costs drop from hundreds to single digits per minute as four platforms dominate $847M market

AI video generation costs drop from hundreds to single digits per minute as four platforms dominate $847M market

Per-minute AI video generation costs fell from several hundred dollars in 2024 to single-digit dollars in 2026, driving enterprise adoption and market consolidation. The global AI video generation sector is projected to reach $847 million in 2026 revenue, with Google's Veo 3.1 and OpenAI leading four dominant platforms. Production teams that once required 50-100 people now operate with fewer than 10.

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com